Alzheimer’s Amyloid Removal: Why Did Tau Differ

What did the Alzheimer’s brain autopsy reveal?

The JAMA case report examined a man who entered an aducanumab trial with mild cognitive impairment and received 30 doses over four and a half years. Researchers combined brain scans collected during life with tissue examination after his death, four years after his final dose. They also included 14 untreated comparison cases. [Original study](https://pubmed.ncbi.nlm.nih.gov/42437499/).

The pattern differed across the brain’s folds. Raised crests, called gyri, more often contained little remaining amyloid and less abnormal tau. Deeper grooves, called sulci, retained more amyloid and showed tau pathology resembling untreated Alzheimer’s disease. MRI measurements associated more complete regional clearance with slower tissue loss. These were associations within one treated brain, rather than a randomized comparison of regional treatment effects. [Study findings](https://pubmed.ncbi.nlm.nih.gov/42437499/).

Why does the relationship between amyloid and tau matter?

Amyloid and tau occupy different places in Alzheimer’s disease: amyloid forms plaques outside nerve cells, while abnormal tau forms tangles inside them. Researchers have long investigated whether amyloid helps create conditions that allow damaging tau changes to develop. Finding markedly different patterns in neighboring tissue provides an unusual opportunity to examine that relationship directly. [Penn Medicine research report](https://www.pennmedicine.org/news/amyloid-removal-may-curb-alzheimers-progression-for-years).

The findings suggest that where clearance occurs may matter alongside how much amyloid disappears overall. That interpretation raises a research question: could improving clearance in less responsive regions produce better outcomes? Penn researchers plan to investigate regional clearance mechanisms and the potential value of earlier treatment. The present evidence cannot establish how much plaque removal is sufficient or whether treatment before symptoms prevents dementia. [Research implications](https://www.pennmedicine.org/news/amyloid-removal-may-curb-alzheimers-progression-for-years).

Does this finding change Alzheimer’s treatment decisions?

One patient cannot represent the full range of Alzheimer’s disease. This participant also carried a TREM2 variant associated with increased disease risk, adding uncertainty about how broadly the findings apply. [Study population](https://pubmed.ncbi.nlm.nih.gov/42437499/). Methodologically, comparing regions within one person helps hold some personal characteristics constant, but those regions can still differ in their underlying biology. Tissue findings alone cannot measure improvements in memory or independence.

Clinical decisions require evidence from treatment trials and an individual assessment. For example, the FDA approved donanemab for Alzheimer’s disease with treatment initiation in the mild cognitive impairment or mild dementia stages. Its trial showed slower clinical decline, rather than recovery of lost abilities. The medicine also carries a boxed warning for amyloid-related imaging abnormalities, including brain swelling and bleeding. This autopsy does not resolve that benefit-risk balance for any individual patient. [FDA treatment evidence and safety information](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease).